Millions of people are touched by diseases related to inflammation and angiogenesis, particularly cancer. Independent research has implicated MetAP2 in many forms of cancer, including:
NSCLC (non-small cell lung cancer),
breast (invasive and metastatic),
GBM (glioblastoma multiforme),
pancreatic cancer, and
TCC (bladder, transitional cell carcinoma), among other.
SynDevRx has assembled an all-star team of clinical oncologists, researchers, professors and drug development experts in an effort to help in the fight against these diseases, and to improve the lives of people living with them.
Our mission is to clinically validate promising therapeutics based on our proprietary technology by advancing them through Phase IIa clinical trials. At that point, we intend on partnering with larger biotech/pharmaceutical companies for completion of Phase IIb and Phase III pivotal trials and FDA drug registration and approval.
Our lead compound has an impressive pedigree; combining research from premier pharmaceutical companies and world-renown research facilities with our own technology. Development is supported by Bruce Zetter, PhD, Dr. Daniel Von Hoff, Dr. Roy Herbst, PhD, Rakesh Jain, PhD., and Dr. Donald Ingber, MD., Ph.D., all recognized leaders in this area of research and treatment, and all key advisors to SynDevRx.
SynDevRx is teaming up with premier research groups to further investigate the mechanism of action of our lead compounds.